Please assess the completion status of the following clinical trial:

Trial Title: Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* CHI diagnosis established based on the following:~  1. Hyperinsulinemia: plasma insulin above the limit of detection of the assay documented during an event of hypoglycemia, and/or~ 2. Hypofattyacidemia: plasma free fatty acid \<1.7 mmol/L, and/or~ 3. Hypoketonemia: Beta-hydroxybutyrate \<1.8 mmol/L, and/or~ 4. Glycemic response: an increase in PG of \>30 mg/dL (1.7 mmol/L) after 1 mg IV or intramuscular (IM) glucagon administration~* Male or female, age ≥7 days and \<12 months at screening~* Body weight of ≥2.0 kg (4.4 lbs.)~* Continuous IV glucose requirement to prevent hypoglycemia~Exclusion Criteria:~* Is suspected of having a transient form of CHI (e.g., transient hyperinsulinism due to maternal diabetes or perinatal stress)~* Was born preterm below 34 weeks of gestational age~* Presence of hypertension or hypotension, including circulatory instability requiring supportive medication or presence of pheochromocytoma~* Known or suspected presence of severe brain damage~* Evidence of metabolic, endocrine, or syndromic causes of hypoglycemia not due to hyperinsulinism~* Use of systemic corticosteroids, e.g., hydrocortisone \>20 mg/m2 body surface area or equivalent within 5 days before screening~* Prior use of lanreotide, sirolimus (mechanistic target of rapamycin (mTOR) inhibitors), anti inflammatory biological agents, or other immune modulating agents. Prior use of octreotide is allowed after a minimum of 48 hour washout before randomization.~* Any clinically significant abnormality identified on echocardiogram that in the opinion of the investigator would affect the subject's ability to participate in the trial~* Any recognized clotting or bleeding disorder~* The use of prescription or non-prescription medications known to cause QT prolongation

- Gender: ALL
- Minimum Age: 7 Days
- Maximum Age: 364 Days
- Healthy Volunteers: f

Study Arms:
- dasiglucagon first then placebo (Type: EXPERIMENTAL): 48 hours of dasiglucagon subcutaneous (sc) infusion starting at 10 µg/hour with crossover to 48 hours placebo sc infusion (part 1) followed by 21 days of dasiglucagon sc infusion (part 2).
- placebo first then dasiglucagon (Type: EXPERIMENTAL): 48 hours of placebo sc infusion with crossover to 48 hours dasiglucagon sc infusion starting at 10 µg/hour (part 1) followed by 21 days of dasiglucagon sc infusion (part 2).

Based on this trial design, predict the completion outcome and termination type (if applicable).